Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy
- Autores
- Hindie, Elif; Zanotti Fregonara, Paolo; Quinto, Michele Arcangelo; Morgat, Clément; Champion, Christophe
- Año de publicación
- 2016
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of90Y,177Lu,111In, and161Tb at irradiating micrometastases.90Y and177Lu are widely used β--emitting radionuclides.161Tb is a medium-energy β-radionuclide that is similar to177Lu but emits a higher percentage of conversion and Auger electrons.111In emits -photons and conversion and Auger electrons. Methods: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of90Y,177Lu,111In, or161Tb in spheres with diameters ranging from 10 mm to 10 m. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per m3, which would result in 160 Gy if totally absorbed. Results: In a 10-mm sphere, the doses delivered by90Y,177Lu,111In, and161Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for90Y. In a 100- m metastasis, the dose delivered by90Y was only 1.36 Gy, compared with 24.5 Gy for177Lu, 38.9 Gy for111In, and 44.5 Gy for161Tb. In cell-sized spheres, the dose delivered by111In and161Tb was higher than that of177Lu. For instance, in a 10- m cell,177Lu delivered 3.92 Gy, compared with 22.8 Gy for111In and 14.1 Gy for161Tb. Conclusion:177Lu,111In, and161Tb might be more appropriate than90Y for treating minimal residual disease.161Tb is a promising radionuclide because it combines the advantages of a medium-energy β-emission with those of Auger electrons and emits fewer photons than111In. 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Fil: Hindie, Elif. Universite de Bordeaux; Francia
Fil: Zanotti Fregonara, Paolo. Universite de Bordeaux; Francia
Fil: Quinto, Michele Arcangelo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universite de Bordeaux; Francia
Fil: Morgat, Clément. Universite de Bordeaux; Francia
Fil: Champion, Christophe. Universite de Bordeaux; Francia - Materia
-
111in
161tb
177lu
90y
Radiopharmaceutical Therapy - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/52884
Ver los metadatos del registro completo
id |
CONICETDig_4de6be485d850aca5b3c3f0ea39b3f2f |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/52884 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapyHindie, ElifZanotti Fregonara, PaoloQuinto, Michele ArcangeloMorgat, ClémentChampion, Christophe111in161tb177lu90yRadiopharmaceutical Therapyhttps://purl.org/becyt/ford/1.3https://purl.org/becyt/ford/1Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of90Y,177Lu,111In, and161Tb at irradiating micrometastases.90Y and177Lu are widely used β--emitting radionuclides.161Tb is a medium-energy β-radionuclide that is similar to177Lu but emits a higher percentage of conversion and Auger electrons.111In emits -photons and conversion and Auger electrons. Methods: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of90Y,177Lu,111In, or161Tb in spheres with diameters ranging from 10 mm to 10 m. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per m3, which would result in 160 Gy if totally absorbed. Results: In a 10-mm sphere, the doses delivered by90Y,177Lu,111In, and161Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for90Y. In a 100- m metastasis, the dose delivered by90Y was only 1.36 Gy, compared with 24.5 Gy for177Lu, 38.9 Gy for111In, and 44.5 Gy for161Tb. In cell-sized spheres, the dose delivered by111In and161Tb was higher than that of177Lu. For instance, in a 10- m cell,177Lu delivered 3.92 Gy, compared with 22.8 Gy for111In and 14.1 Gy for161Tb. Conclusion:177Lu,111In, and161Tb might be more appropriate than90Y for treating minimal residual disease.161Tb is a promising radionuclide because it combines the advantages of a medium-energy β-emission with those of Auger electrons and emits fewer photons than111In. 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.Fil: Hindie, Elif. Universite de Bordeaux; FranciaFil: Zanotti Fregonara, Paolo. Universite de Bordeaux; FranciaFil: Quinto, Michele Arcangelo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universite de Bordeaux; FranciaFil: Morgat, Clément. Universite de Bordeaux; FranciaFil: Champion, Christophe. Universite de Bordeaux; FranciaSociety of Nuclear Medicine and Molecular Imaging2016-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/52884Hindie, Elif; Zanotti Fregonara, Paolo; Quinto, Michele Arcangelo; Morgat, Clément; Champion, Christophe; Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy; Society of Nuclear Medicine and Molecular Imaging; Journal of Nuclear Medicine; 57; 5; 5-2016; 759-7640161-5505CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://jnm.snmjournals.org/content/57/5/759info:eu-repo/semantics/altIdentifier/doi/10.2967/jnumed.115.170423info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:36:19Zoai:ri.conicet.gov.ar:11336/52884instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:36:19.655CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy |
title |
Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy |
spellingShingle |
Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy Hindie, Elif 111in 161tb 177lu 90y Radiopharmaceutical Therapy |
title_short |
Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy |
title_full |
Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy |
title_fullStr |
Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy |
title_full_unstemmed |
Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy |
title_sort |
Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy |
dc.creator.none.fl_str_mv |
Hindie, Elif Zanotti Fregonara, Paolo Quinto, Michele Arcangelo Morgat, Clément Champion, Christophe |
author |
Hindie, Elif |
author_facet |
Hindie, Elif Zanotti Fregonara, Paolo Quinto, Michele Arcangelo Morgat, Clément Champion, Christophe |
author_role |
author |
author2 |
Zanotti Fregonara, Paolo Quinto, Michele Arcangelo Morgat, Clément Champion, Christophe |
author2_role |
author author author author |
dc.subject.none.fl_str_mv |
111in 161tb 177lu 90y Radiopharmaceutical Therapy |
topic |
111in 161tb 177lu 90y Radiopharmaceutical Therapy |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.3 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of90Y,177Lu,111In, and161Tb at irradiating micrometastases.90Y and177Lu are widely used β--emitting radionuclides.161Tb is a medium-energy β-radionuclide that is similar to177Lu but emits a higher percentage of conversion and Auger electrons.111In emits -photons and conversion and Auger electrons. Methods: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of90Y,177Lu,111In, or161Tb in spheres with diameters ranging from 10 mm to 10 m. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per m3, which would result in 160 Gy if totally absorbed. Results: In a 10-mm sphere, the doses delivered by90Y,177Lu,111In, and161Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for90Y. In a 100- m metastasis, the dose delivered by90Y was only 1.36 Gy, compared with 24.5 Gy for177Lu, 38.9 Gy for111In, and 44.5 Gy for161Tb. In cell-sized spheres, the dose delivered by111In and161Tb was higher than that of177Lu. For instance, in a 10- m cell,177Lu delivered 3.92 Gy, compared with 22.8 Gy for111In and 14.1 Gy for161Tb. Conclusion:177Lu,111In, and161Tb might be more appropriate than90Y for treating minimal residual disease.161Tb is a promising radionuclide because it combines the advantages of a medium-energy β-emission with those of Auger electrons and emits fewer photons than111In. 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc. Fil: Hindie, Elif. Universite de Bordeaux; Francia Fil: Zanotti Fregonara, Paolo. Universite de Bordeaux; Francia Fil: Quinto, Michele Arcangelo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universite de Bordeaux; Francia Fil: Morgat, Clément. Universite de Bordeaux; Francia Fil: Champion, Christophe. Universite de Bordeaux; Francia |
description |
Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of90Y,177Lu,111In, and161Tb at irradiating micrometastases.90Y and177Lu are widely used β--emitting radionuclides.161Tb is a medium-energy β-radionuclide that is similar to177Lu but emits a higher percentage of conversion and Auger electrons.111In emits -photons and conversion and Auger electrons. Methods: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of90Y,177Lu,111In, or161Tb in spheres with diameters ranging from 10 mm to 10 m. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per m3, which would result in 160 Gy if totally absorbed. Results: In a 10-mm sphere, the doses delivered by90Y,177Lu,111In, and161Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for90Y. In a 100- m metastasis, the dose delivered by90Y was only 1.36 Gy, compared with 24.5 Gy for177Lu, 38.9 Gy for111In, and 44.5 Gy for161Tb. In cell-sized spheres, the dose delivered by111In and161Tb was higher than that of177Lu. For instance, in a 10- m cell,177Lu delivered 3.92 Gy, compared with 22.8 Gy for111In and 14.1 Gy for161Tb. Conclusion:177Lu,111In, and161Tb might be more appropriate than90Y for treating minimal residual disease.161Tb is a promising radionuclide because it combines the advantages of a medium-energy β-emission with those of Auger electrons and emits fewer photons than111In. 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-05 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/52884 Hindie, Elif; Zanotti Fregonara, Paolo; Quinto, Michele Arcangelo; Morgat, Clément; Champion, Christophe; Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy; Society of Nuclear Medicine and Molecular Imaging; Journal of Nuclear Medicine; 57; 5; 5-2016; 759-764 0161-5505 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/52884 |
identifier_str_mv |
Hindie, Elif; Zanotti Fregonara, Paolo; Quinto, Michele Arcangelo; Morgat, Clément; Champion, Christophe; Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy; Society of Nuclear Medicine and Molecular Imaging; Journal of Nuclear Medicine; 57; 5; 5-2016; 759-764 0161-5505 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://jnm.snmjournals.org/content/57/5/759 info:eu-repo/semantics/altIdentifier/doi/10.2967/jnumed.115.170423 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Society of Nuclear Medicine and Molecular Imaging |
publisher.none.fl_str_mv |
Society of Nuclear Medicine and Molecular Imaging |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614383362113536 |
score |
13.070432 |